title: Efficacy of Procox® oral suspension for dogs (0.1% emodepside and 2% toltrazuril) against experimental nematode (Toxocara cati and Ancylostoma tubaeforme) infections in cats.
abstract: Two exploratory studies were performed to determine the optimum therapeutic dose of Procox(®) for the removal of experimental infection with mature adult Toxocara (T.) cati and Ancylostoma (A.) tubaeforme in kittens. Procox(®) is a new oral suspension containing a combination of the nematocidal and coccidiocidal active principles emodepside (0.1 %) and toltrazuril (2 %).In the first study, 18 eight-weeks-old kittens were inoculated with 450 L3 larvae of T. cati. 56 days after infection, the kittens were allocated to three treatment groups and were treated with 0.5 mg emodepside/kg body weight (group 1), 0.25 mg emodepside/kg body weight (group 2) and 0.1 mg emodepside/kg body weight (group 3), respectively. In the second study, 10 eight-weeks-old kittens were inoculated with 350 L3 larvae of A. tubaeforme. Four weeks after infection, the kittens were allocated to two treatment groups and were treated with 0.1 mg emodepside/kg body weight (group 1) or 0.25 mg emodepside/kg body weight (group 2). In both studies, all kittens received a reference treatment with Drontal(®) (230 mg pyrantel embonate and 20 mg praziquantel per tablet) at the recommended dose of one tablet/4 kg body weight 5 days after treatment with Procox(®). Anthelmintic efficacy was calculated by reduction in worm numbers expelled with the faeces following treatment with Procox(®) as compared with faecal worm numbers after reference treatment with Drontal(®), by thus avoiding necropsy of the animals.In the T. cati study, emodepside was at 99.9 %, 100 % and 96.5 % effective at a dosage of 0.5 mg, 0.25 mg and 0.1 mg per kg body weight, respectively. Against A. tubaeforme emodepside was at 95.7 % and 100 % effective at a dosage of 0.1 mg and 0.25 mg per kg body weight. No adverse events were seen during either study.It can be concluded that Procox(®) is efficacious for the control of mature adult T. cati and A. tubaeforme infections in cats at a single-dose rate of 0.25 mg emodepside/kg body weight.
authors: Bayer Animal Health GmbH, Leverkusen, Germany. gabriele.petry@bayer.com
authors: Gabriele
authors: G
authors: Petry
authors: Eva
authors: E
authors: Kruedewagen
authors: Thomas
authors: T
authors: Bach
authors: Nadine
authors: N
authors: Gasda
authors: Klemens J
authors: KJ
authors: Krieger
mesh_terms: D000284:Administration, Oral; D000722:Ancylostoma / Q000187:drug effects*; D000724:Ancylostomiasis / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D000818:Animals; D000969:Antinematodal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002371:Cat Diseases / Q000188:drug therapy* / Q000469:parasitology; D002415:Cats; D047630:Depsipeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D007814:Larva / Q000187:drug effects / Q000472:pathogenicity; D010270:Parasite Egg Count / Q000662:veterinary; D014119:Toxocara / Q000187:drug effects*; D014120:Toxocariasis / Q000188:drug therapy* / Q000469:parasitology; D014227:Triazines / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000969:Antinematodal Agents; D047630:Depsipeptides; D004338:Drug Combinations; D014227:Triazines; C036670:toltrazuril; C468987:emodepside